Wang Dan, Wei Jing, Feng Yi-Mei, Zhang Xi
Department of Hematology, The Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China.
Medical Center of Hematology, The Xinqiao Hospital of Army Medical University, Chongqing 400037, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Feb;32(1):302-307. doi: 10.19746/j.cnki.issn.1009-2137.2024.01.049.
Graft-versus-host disease (GVHD) reduces the clinical effect and life quality of patients after allogeneic hematopoietic stem cell transplantation (HSCT). Especially for steroid-resistant GVHD, it becomes essential to explore new prevention and treatment strategies. Rapamycin has shown certain clinical advantages in the prevention and treatment of acute and chronic GVHD by inhibiting the mTOR signal pathway. Furthermore, rapamycin exhibits the ability to regulate cell subsets, including T cells, B cell, dendritic cells and myeloidderived suppressor cells, which elucidates the mechanism on effective preventing and treating GVHD. This article reviewed the roles of mTOR inhibitor-rapamycin on GVHD, and discussed how to optimize the usage of rapamycin.
移植物抗宿主病（GVHD）会降低异基因造血干细胞移植（HSCT）后患者的临床疗效和生活质量。尤其是对于类固醇难治性GVHD，探索新的预防和治疗策略变得至关重要。雷帕霉素通过抑制mTOR信号通路，在急性和慢性GVHD的预防和治疗中显示出一定的临床优势。此外，雷帕霉素具有调节细胞亚群的能力，包括T细胞、B细胞、树突状细胞和髓源性抑制细胞，这阐明了其有效预防和治疗GVHD的机制。本文综述了mTOR抑制剂雷帕霉素在GVHD中的作用，并探讨了如何优化雷帕霉素的使用。
